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Abstract
Chemotherapy-induced amenorrhea (CIA) often occurs in pre- and peri-menopausal BC patients,
and while cancer/chemotherapy and abrupt estrogen loss have separately been shown to affect
cognition and brain function, studies of the cognitive effects of CIA are equivocal, and its effects
on brain function are unknown. Functional MRI (fMRI) during a working memory task was used
to prospectively assess the pattern of brain activation and deactivation prior to and one month after
chemotherapy in BC patients who experienced CIA (n=9), post-menopausal BC patients
undergoing chemotherapy (n=9), and pre- and post-menopausal healthy controls (n=6 each).
Neurocognitive testing was also performed at both time points. Repeated measures general linear
models were used to assess statistical significance, and age was a covariate in all analyses. We
observed a group-by-time interaction in the combined magnitudes of brain activation and
deactivation (p = 0.006): the CIA group increased in magnitude from baseline to post-treatment
while other groups maintained similar levels over time. Further, the change in brain activity
magnitude in CIA was strongly correlated with change in processing speed neurocognitive testing
score (r=0.837 p=0.005), suggesting this increase in brain activity reflects effective cognitive
compensation. Our results demonstrate prospectively that the pattern of change in brain activity
from pre- to post-chemotherapy varies according to pre-treatment menopausal status. Cognitive
correlates add to the potential clinical significance of these findings. These findings have
implications for risk appraisal and development of prevention or treatment strategies for cognitive
changes in CIA.
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Cancer and its treatments have been linked to cognitive dysfunction, particularly in the
executive function, working memory, processing speed, verbal, and visuospatial domains
(Jansen et al. 2005; Jim et al. 2012). Approximately 80% of pre- or peri-menopausal breast
cancer (BC) patients undergoing current widely used chemotherapy (CTx) regimens
(cyclophosphamide and doxorubicin, with or without a taxane) experience chemotherapy-
induced amenorrhea (CIA) in the months immediately following CTx (Petrek et al. 2006;
Minisini et al. 2009; Swain et al. 2009; Swain et al. 2010). CIA results from disruption of
normal ovarian follicular maturation, leading to markedly decreased systemic estrogen
levels (Warne et al. 1973), and is associated with increased survival (Walshe et al. 2006;
Swain et al. 2010). As abrupt estrogen loss in pre-menopausal women has been linked to
cognitive dysfunction (Vearncombe and Pachana 2009), it is plausible that CIA may lead to
increased detrimental effects of CTx compared to women who undergo CTx but not CIA
(usually BC patients post-menopausal before CTx). Indeed, prospective studies have shown
decline or failure to improve with practice in multiple cognitive domains in patients
undergoing CIA compared to patients undergoing CTx but not amenorrhea (Jenkins et al.
2006; Vearncombe et al. 2011), although other studies found no such effect (Schagen et al.
2006; Hermelink et al. 2007; Hermelink et al. 2008). Timing of measurements appears to
play a role.
Prospective functional neuroimaging has the power to observe, in the face of a neural insult
such as CTx or estrogen loss, how the brain might compensate (in the context of maintained
cognitive performance), or fail to adapt (in the context of decreased performance). We
recently showed pre-treatment frontal hyperactivation in BC during a working memory task,
with a decrease in activation in this region one month post-CTx accompanied by decreased
working memory performance (McDonald et al. 2012). Performance and activation returned
to higher levels one year later. The neural effects of abrupt estrogen loss in pre-menopausal
women have been studied prospectively with gonadotropin hormone releasing hormone
(GnRH) agonists. These studies generally show that estrogen ablation is associated with
reversible decreased task-related activation (Berman et al. 1997; Craig et al. 2007; Craig et
al. 2008; Craig et al. 2008). However, the neural effects of CIA remain unclear.
The aim of this study was to prospectively measure global changes in working memory-
related activation and deactivation, before cancer treatment and one month post-CTx
completion. During a cognitive task, brain activation increases in “task-positive network”
regions, while task-induced deactivation occurs in the anatomical regions of the “default
mode network” (DMN) in a reallocation of neural resources (Fox et al. 2005). Both
activation and deactivation are important in cognition, and both are affected by normal aging
as well as pathological conditions. While activation and deactivation occur in
complementary brain regions during a particular task, they can be differentially affected by
pathological processes. Drawing on participants in our previous prospective fMRI study of
BC patients (McDonald et al. 2012), we examined working memory-related activation and
deactivation in BC patients who underwent CIA (i.e., pre- or perimenopausal patients) and
patients who were post-menopausal at CTx initiation. Pre- and post-menopausal healthy
control (HC) groups were imaged at yoked intervals. We hypothesized that the CIA profile
of activation and deactivation during a working memory task would be distinct from that of
HC or post-menopausal CTx, and that these changes over time would be correlated with
changes seen in neurocognitive performance.
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Appropriate cases were selected from our previous fMRI study (McDonald et al. 2012) who
fit the following categories: post-menopausal BC patients undergoing CTx (n=9), pre- or
peri-menopausal BC patients undergoing CTx (n=9), pre- and post-menopausal HC (n=6
each). Scans and neuropsychological measures were collected post-surgery but prior to any
other cancer treatment (baseline; BL) and one month post-CTx completion (M1) or yoked
intervals for HC.
Patients had stage I, II, or IIIA BC treated with standard-dose AC or AC-T CTx regimens
(Table 1). Exclusion criteria included prior cancer or cancer treatment and medical,
neurological, and psychiatric risk factors known to affect brain structure or function, as
detailed previously (McDonald et al. 2010). Depressive symptoms and anxiety were
assessed with the Center for Epidemiologic Studies-Depression Scale (CES-D) (Radloff
1977) and the State-Trait Anxiety Inventory-State subscale (STAI-S) (Spielberger 1983).
Written informed consent was obtained according to the Declaration of Helsinki under a
protocol approved by the Dartmouth College Committee for the Protection of Human
Subjects.
MRI Scans
Scans were acquired on a 1.5T GE Signa LX scanner with echospeed gradients and standard
head coil. A gradient-echo, echo-planar sequence provided whole brain coverage for fMRI:
TR=2500ms, TE=40ms, FOV=24cm, NEX=1, 29 interleaved 5mm thick contiguous sagittal
slices, yielding a 64×64 matrix with 3.75mm2 in-plane resolution. Structural scans were
acquired to rule out incidental pathology and for the previously reported gray matter density
analysis (McDonald et al. 2010).
An auditory-verbal “N-back” task was used as in our previous study (McDonald et al. 2012).
During scanning participants heard a string of consonant letters (except L, W, and Y)
presented one every three seconds. Task conditions were 0-, 1-, 2-, and 3-back, in a blocked
design. For each consonant participants used a button press device to signify whether the
current letter was a match (i.e., was the same as the designated target or the letter presented
1, 2, or 3 back in the sequence) or a non-match. Each condition was presented in 27-second
epochs preceded by three seconds of instruction (e.g., “the match is one back”). The four
experimental conditions were each presented three times in pseudo-random order for a total
of 12 task blocks. Participants rehearsed a practice version of the task prior to scanning to
ensure comprehension of task demands. Stimuli were presented through an MRI compatible
headphone system, and programmed in Presentation software (Neurobehavioral Systems,
Inc., Albany, CA), which recorded response accuracy and reaction times.
Using raw scan data, spatial realignment using a six parameter model was performed in
SPM5. Realignment parameters were entered as covariates at the subject level, and volumes
were normalized into MNI space, resampled to 2mm3 voxels, and smoothed to a FWHM of
8mm. Statistical parametric mapping on a voxel-by-voxel basis was conducted using a
general linear model (GLM) approach. Contrast images comparing pairs of working
memory load conditions (e.g., 3-back > 0-back) were created for each subject.
To derive numerical values for activation and deactivation during the 3-back task, all 3-back
> 0-back contrast images were entered into a one-sample t-test in SPM5. Maps were created
for activation (“task-positive network”; contrast vector 1; i.e., 3-back > 0-back) and
deactivation (“default mode network”; contrast vector −1; i.e., 0-back > 3-back) at pcrit =
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0.05, cluster minimum size (k) = 10 voxels. MarsBar v. 0.42 (Brett et al. 2002) was used to
extract mean values for each participant’s activation and deactivation in the appropriate
anatomical regions at both time points. Our imaging analyses used three dependent
measures: total activation, total deactivation, and the summed magnitudes of activation and
deactivation (as a measure of overall neural change in response to the task).
Neurocognitive Testing Domains
Raw neurocognitive test scores were normalized using the mean and standard deviation of
the larger HC group from which HC subjects for the current study were drawn (demographic
data regarding the larger cohort can be found in (McDonald et al. 2010)). Alternate test
forms were used at each study visit where possible. Domain scores were created for each
subject by averaging the z-scores of the included tests, similar to our prior cognitive studies
(Ahles et al. 2008; Ahles et al. 2010), and were then adjusted for age using the entire sample
of the current study. The verbal domain was calculated using the Wide Range Achievement
Test (WRAT-3) reading score (Wilkinson 1993), the Wechsler Abbreviated Scale of
Intelligence (WASI) Vocabulary score (The Psychological Corporation 1999), and the
Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test phonemic and
semantic trial scores (Delis et al. 2001). The verbal memory domain consisted of the
California Verbal Learning Test (CVLT or CVLT-II) total and delayed free recall scores
(Delis et al. 2000; Delis et al. 1987) and the Craft story immediate and delayed recall scores
(Craft et al. 1996). The visual memory domain was the Brown Learning Test initial learning
trials and delayed recall score (Brown et al. 2007). The working memory score consisted of
the Rao Paced Auditory Serial Addition Test (PASAT) 2 and 3 second trial totals (Fischer et
al. 2001). The processing speed score comprised the WAIS-III Digit Symbol-Coding score
(The Psychological Corporation 1997), the left- and right-hand grooved pegboard times
(Lafayette Instrument 1989), and completion times from D-KEFS Trail Making Test trials
1–5 and the D-KEFS Color-Word Interference Test color naming, word reading, and color-
word interference trials. The sorting domain was the D-KEFS Sorting Test number of
correct sorts and the free sorting and recognition trial description scores. The distractibility
domain was the Gordon Continuous Performance Task (CPT) distractibility trial total
correct and false positive scores, while the reaction time domain was the average of the CPT
distractibility and vigilance trial reaction times. The global score was the average of all the
above domains as well as the WASI Block Design score.
Statistical Analyses
One-way ANOVA with Tukey post-hoc tests were used to examine between-group effects
of age, education, IQ estimates, and BL-M1 interval, while chi-square examined handedness
distribution. Experimental measures, including fMRI activation and deactivation,
neuropsychological tests, 3-back task performance and reaction times, and depression and
anxiety scores were assessed using a repeated measures general linear model in SPSS 19
with factors of group and time. Age covariates were used in imaging analyses, while
neuropsychological measures were pre-adjusted for age. Group-by-time interactions from
these analyses were examined, as well as main effects of group and time. Absolute values of
activation and deactivation were summed at each time point to create a measure of total
change in neural activity and analyzed using the same repeated measures model. Pearson
correlations were used to assess relationships between changes in imaging variables and
neuropsychological values.
Results
Demographics, psychological state, hormonal status and cancer treatment data are provided
in Table 1. As expected, groups differed in age, with both post-menopausal groups
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significantly older than both pre-menopausal groups at baseline (overall ANOVA p<0.001;
post-hoc Tukey tests p<0.05)
Education, handedness, estimated IQ, and BL-M1 interval did not differ between groups.
CES-D and STAI-S mean scores were well below clinical thresholds and did not show main
effects of group or time or group-by-time interactions. Several cancer patients were using
psychiatric medications at each study visit, with little change in medication regimens
between BL and M1. Cancer stage and CTx regimens were similar between groups.
All post-menopausal HC and CTx participants reported amenorrhea >6 months at study
entry, and all pre-menopausal HC had regular periods at study entry (Table 1). In the CIA
group, 4 patients reported regular periods and 3 patients reported irregular periods at study
entry, and all of these reported amenorrhea >6 months related to CTx at M1. Menstrual
status was unavailable for 2 CIA patients, but they were placed in this group based on their
ages of 44 and 45 at study entry, as all HC under 50 in this cohort were pre-menopausal. For
hormonal medications, several post-menopausal patients reported using hormonal
replacement therapy at each visit (4 at BL, 2 at M1). One 55-year-old CIA participant (the
oldest in this group) was using estrogen for perimenopausal symptoms at BL but had
stopped at M1. No cancer patients were using antiestrogen treatments at BL, but 2 patients
in each cancer group had started these treatments at M1.
Figure 1 depicts the activation and deactivation regions of interest used to derive values for
each participant at BL and M1. Figure 2a shows mean values of activation and deactivation
for each group at BL and M1. Repeated measures ANOVA with an age covariate did not
show any significant main effects or interactions for either activation or deactivation.
Repeated measures ANOVA on the summed magnitudes of activation and deactivation for
the four groups with an age covariate revealed a significant group-by-time interaction
(p=0.006). In contrast to the other groups, the CIA group showed an increase in the summed
magnitudes of activation and deactivation from BL to M1 (Figures 2b, 2c), and this change
was statistically significant (p=0.011). There was also a significant effect of time (p=0.046),
with an overall pattern of increased magnitudes from BL to M1 and a time-by-age
interaction (p=0.047) in which younger participants tended to increase in magnitude over
time (driven by the CIA group).
In-scanner 3-back task performance and reaction times did not differ between groups or over
time (Table 2).
Group means of neuropsychological testing domains are shown in Table 2. A main effect of
time was present for most domains at p ≤0.01. This reflected an overall tendency toward
improved performance at M1, likely due to practice effects. Main effect of group was not
statistically significant in any domain. Interestingly, trends toward group-by-time
interactions were present in the verbal (p=0.073) and visual memory (p=0.098) domains. In
both of these domains, all groups showed improved performance from BL to M1 except for
the CTx post-menopausal group, whose performance decreased between sessions.
To assess the functional significance of the increased magnitude of neural activity in CIA,
we tested for correlations between the activity change in this group and change in
neuropsychological domain scores. A significant positive correlation emerged in the
processing speed domain (r=0.837, p=0.005, survives Bonferroni threshold for 9 domains
(p=0.045 after correction); Figure 3). The positive valence indicates that increased
magnitude of neural activation/deactivation between BL and M1 is associated with
improvement in processing speed scores. No other CIA activity change-neurocognitive
domain correlations were statistically significant.
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Our results demonstrate prospectively that the pattern of change in brain activity from pre-
to post-CTx varies according to pre-treatment menopausal status. BC patients who
underwent CIA showed increased magnitudes of activation and deactivation from pre- to
post-CTx, while CTx post-menopausal and both HC groups did not. In the context of
maintained 3-back task performance, this may indicate effective compensatory neural
activity in the CIA group. Age, an inevitable between-group confound in this type of
analysis, was included as a covariate, suggesting that these effects are due to CIA itself. We
found no evidence for the negative cognitive effect of CIA that has been observed in some
studies (Jenkins et al. 2006; Vearncombe et al. 2011) but not others (Schagen et al. 2006;
Hermelink et al. 2007; Hermelink et al. 2008), although multiple studies of women in this
demographic who undergo abrupt loss of ovarian function via surgical menopause suggest
that larger samples of CIA patients may well demonstrate this effect (Henderson and
Sherwin 2007; Vearncombe and Pachana 2009).
Relationships between brain changes and behavioral measures increase the potential clinical
significance of our findings. CIA-related change in neural activity was highly correlated
with improvement in neurocognitive processing speed scores from BL to M1, suggesting
that this adaptation is functional. Processing speed has been shown prospectively to be the
domain most sensitive to chemotherapy-related change (Ahles et al. 2010), in addition to
being one of several domains most implicated in cancer- and treatment-related cognitive
dysfunction (Jansen et al. 2005),
The current results are consistent with the interpretation that the neural stress of CIA’s
abrupt decrease in estrogen, in addition to CTx itself, requires alterations in brain activity to
maintain cognitive function. In light of evidence that both activation (Nagel et al. 2011) and
deactivation (McKiernan et al. 2003) increase parametrically with task demand, these results
suggest that after CTx, the CIA brain responds to the same 3-back task as if it is more
difficult. A similar phenomenon of effective compensatory activation has been observed in
mild cognitive impairment (MCI) in older adults: in the early, higher functioning stages of
MCI, patients show hippocampal and prefrontal hyperactivation during memory tasks
compared to cognitively normal older adults, while activation decreases in later stages of
MCI as cognitive functioning declines (Clement and Belleville 2010; O'Brien et al. 2010).
Interestingly, in neuropsychological testing, the post-menopausal CTx group was unable to
maintain performance in the post-CTx visit, while in all other groups scores improved
between BL and M1 in the verbal and visual memory domains (in non-significant trends for
group-by-time interactions). These domains involve different neural circuitry than the
working memory scanner task and have not been especially previously implicated in CTx-
related cognitive dysfunction, but the lack of increase in neural activity in the post-
menopausal CTx group may be related to this decreased neurocognitive performance post-
treatment. As estrogen loss reduces neuroplasticity, and longer duration of estrogen
deprivation (i.e., more time after menopause) is associated with worse outcomes (Brinton
2009), the lack of change in brain activity may be related to reduced neuroplastic adaptation
to CTx in the post-menopausal brain. This result is also consistent with a recent longitudinal
study (Ahles et al. 2010) which found that older age was related to increased risk for
cognitive dysfunction after CTx, particularly in the context of processing speed domain and
lower cognitive reserve (although no effects of pre-treatment menopausal status were
observed). Follow-up of cognitive results in larger cohorts is warranted.
While there are no neuroimaging studies of CIA with which to compare the current results,
neuroimaging studies of both cancer/CTx and estrogen suppression in pre-menopausal
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women do exist. In cancer and CTx, BC patients have shown pre-treatment frontal
hyperactivation (Cimprich et al. 2010; McDonald et al. 2012) that is attenuated one month
post-CTx but remains hyperactive one year later (McDonald et al. 2012). Task performance
tended to decrease along with the attenuation of hyperactivation at one month and return to
higher levels one year later (McDonald et al. 2012). Studies of longer-term survivors with a
history of CTx have demonstrated lower activation in task-related regions (de Ruiter et al.
2011; Kesler et al. 2011). Prospective studies of pre-menopausal women who undergo
abrupt estrogen suppression with gonadotropin releasing hormone (GnRH) agonists have
shown globally attenuated task-related blood flow on PET in the context of maintained task
performance (Berman et al. 1997), and decreased frontal fMRI activation during memory
encoding with a trend toward worse performance on the subsequent recognition test (Craig
et al. 2007). It is notable that in the GnRH agonist studies, estrogen is still being suppressed
at the time of scanning, while at M1 in the current study, ovarian function may be starting to
resume after CIA and several patients were using tamoxifen, which also affects estrogen
function. All of the above studies measured regionally specific task-related activation, while
the current study focuses on global levels of activation and deactivation, so direct
comparison is difficult.
The effects of cancer and CTx on cognition and brain activity likely involve multiple
biological pathways (Ahles and Saykin 2007), and the present results contribute to a better
understanding of one key pathway, hormonal changes. Possible mechanisms for CTx-related
cognitive dysfunction, including oxidative stress and genetic factors, overlap with those
thought to be involved in the deleterious effects of estrogen loss (Stearns et al. 2006; Ahles
and Saykin 2007; Henderson and Brinton 2010), suggesting possible compounding effects.
This study has several strengths. To our knowledge, this is the first neuroimaging study of
CIA. The study is prospective, increasing confidence in attribution of brain effects to CIA.
Two groups of HC were employed to match the CIA and post-menopausal CTx groups. Our
analyses employed either an age covariate or data pre-adjusted for age, minimizing the
effects of this potential confound. Comprehensive neuropsychological testing was conducted
in order to determine domain-specific effects of treatment. Finally, the strong correlation in
CIA between changes in neural activity and processing speed is promising for the behavioral
relevance of these results.
This study also has several limitations. First, the sample sizes are modest, commensurate
with the difficulty of recruiting BC patients prospectively for a time-consuming study. Pre-
and peri-menopausal BC patients were included in the CIA group, potentially increasing
variability. We relied on self-reported menstrual status at each session rather than hormone
levels; future work correlating cognitive and imaging variables with hormone levels would
be informative. Several of our BC patients used antidepressants and post-CTx anti-estrogen
therapy, which is difficult to avoid in this population, and several post-menopausal HC
participants were using hormone replacement therapy. Larger studies testing the neural
effects of anti-estrogen treatments as well as previous hormone replacement therapy in the
BC population will be informative. Finally, we report here objective neuropsychcological
testing results; assessment of self-reported cognitive complaints would also be interesting in
the context of CIA, as increased cognitive complaints have been reported in a range of
patients undergoing breast cancer treatment (Pullens et al. 2010).
Subsequent studies should follow the effects of CIA longitudinally. While 80% of pre- and
peri-menopausal BC patients experience CIA in the months immediately following CTx
(Petrek et al. 2006; Minisini et al. 2009; Swain et al. 2009; Swain et al. 2010), only 20–60%
remain amenorrheic 6–12 months later (Minisini et al. 2009; Sukumvanich et al. 2010; Ganz
et al. 2011). Complicating matters, tamoxifen has been shown to potentiate CIA (Ganz et al.
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2011), and post-menopausal CTx comparison groups will likely be using aromatase
inhibitors, which may have different neural effects than tamoxifen. While estrogen is
neurotrophic and neuroprotective in vitro, the effects of estrogen loss (and replacement) on
the human brain are complicated and controversial (Turgeon et al. 2006; Sukumvanich et al.
2010), and CIA is no exception. Despite these complications, it will be important to
determine the neural effects of CIA throughout survivorship. Other types of fMRI analyses
(voxelwise, resting state, etc.) will also be informative, as estrogen influences both structural
and functional connectivity (Peper et al. 2011). While BC patients cannot be treated with
any agent that is an estrogen agonist to breast tissue, future intervention with other agents,
such as specially designed “neuro-SERMs” (Zhao et al. 2005; Doncarlos et al. 2009), which
might be estrogen antagonists to breast and uterus and estrogen agonists to brain and bone,
may prove beneficial. The current findings have implications for risk appraisal and
development of prevention or intervention strategies for cognitive changes in CIA.
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Working memory-related (a) activation (3-back > 0-back contrast) and (b) deactivation (0-
back > 3-back contrast) regions of interest derived from main effects of all groups’ baseline
and one month post-chemotherapy scans; pcrit=0.05, minimum cluster extent (k)=10.
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(a) Working memory-related total activation and deactivation at baseline (BL) and 1 month
post-chemotherapy (M1) (arbitrary units; mean±SD). (b) Summed magnitudes of activation
and deactivation at BL and M1; group-by-time interaction is statistically significant
(p=0.006), with only the CIA group showing change over time (p=0.011). (c) Change
between BL and M1 in summed magnitudes of activation and deactivation.
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Correlation of change in summed magnitude of activation and deactivation with change in
processing speed neuropsychological testing domain scores from baseline to one month
post-chemotherapy in chemotherapy-induced amenorrhea (CIA) (r=0.837, p=0.045 after
Bonferroni correction for 9 neuropsychological domains).
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